Today's Stock Price Targets and Analyst Ratings

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
AAPL Apple	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wamsi Mohan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$337.02 -0.8%	$370.00	Buy
ABF Associated British Foods	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 1,828 -1.5%	GBX 1,550 ➝ GBX 1,520	Sector perform
ABSI Absci	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.74 -9.1%	$11.00	Buy
ACAD ACADIA Pharmaceuticals	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Hershenhorn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.43 -3.7%		Market Perform
ACHC Acadia Healthcare	Target Raised by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whit Mayo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.51 -2.9%	$30.00 ➝ $33.00	Market Perform
ACN Accenture	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keith Bachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$183.46 -0.1%	$150.00 ➝ $200.00	Market Perform
ADUR Aduro Clean Technologies	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Amit Dayal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$12.68 +0.1%	$22.00	Buy
AGX Silver X Mining	Target Raised by	Ventum Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$0.95 -4.0%	C$1.60 ➝ C$2.50
AKR Acadia Realty Trust	Reiterated by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Todd M. Thomas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.12 -1.3%		Overweight
ALK Alaska Air Group	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tom Fitzgerald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$39.66 -5.4%		Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
ALLY Ally Financial	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$38.54 -1.4%	$51.00 ➝ $50.00	Buy
ALT Altimmune	Reiterated by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$3.19 -6.5%		Outperform
ALV Autoliv	Downgraded by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Rosner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$115.45 -2.8%		Outperform ➝ Peer Perform
AMGN Amgen	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$406.09 -1.0%		Outperform
AMGN Amgen	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$406.09 -1.0%	$410.00	Hold
AMRX Amneal Pharmaceuticals	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.33 -0.9%	$27.00	Outperform
AMRZ Amrize	Target Lowered by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jon Bell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.87 -2.9%	$64.00 ➝ $56.00	Buy
ANAB AnaptysBio	Target Lowered by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$50.77 -5.8%	$90.00 ➝ $81.00	Outperform
ANIP ANI Pharmaceuticals	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$74.43 -4.5%	$85.00	Market Perform
APH Amphenol	Initiated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Varun Govindaraj Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$82.30 -0.7%	$99.00	Outperform
APLD Applied Digital	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$27.23 -4.6%	$38.00	Market Outperform ➝ Buy
ARX Accelerant	Downgraded by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	C. Gregory Peters Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.73 -0.3%		Market Perform ➝ Underperform
AURR Aurrigo International	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 115 -5.3%	GBX 175	Speculative Buy
AVEX AEVEX	Initiated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sheila Kahyaoglu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.40 +3.1%	$26.00	Buy
AXP American Express	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$301.56 -1.1%	$375.00 ➝ $370.00	Buy
AXSM Axsome Therapeutics	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$193.45 -4.8%	$200.00 ➝ $285.00	Buy
AZO AutoZone	Reiterated by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2,848.16 -1.6%		Outperform
AZO AutoZone	Target Set by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Nagel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,400.00
AZO AutoZone	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seth Sigman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,637.00 ➝ $3,400.00	Overweight
AZO AutoZone	Target Lowered by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Forbes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$4,000.00 ➝ $3,750.00	Buy
AZO AutoZone	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scot Ciccarelli Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,817.00 ➝ $3,648.00	Buy
AZO AutoZone	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Lasser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,850.00
AZO AutoZone	Target Lowered by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bobby Griffin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$4,000.00 ➝ $3,700.00	Strong-Buy
AZO AutoZone	Target Lowered by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Rakhlenko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,500.00 ➝ $3,400.00	Buy
AZO AutoZone	Target Lowered by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Baker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,750.00 ➝ $3,500.00	Buy
AZO AutoZone	Target Lowered by	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Stember Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$4,023.00 ➝ $3,850.00	Buy
AZO AutoZone	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Kleber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,600.00 ➝ $3,400.00	Neutral
AZO AutoZone	Target Lowered by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bobby Griffin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$4,000.00 ➝ $3,700.00	Strong-Buy
AZO AutoZone	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bellinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$3,200.00 ➝ $3,000.00	Neutral
AZO AutoZone	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tristan Thomas-Martin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,848.16 -1.6%	$4,000.00 ➝ $3,500.00	Outperform
Here’s the stock symbol I’ve promised (Ad) Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. Get the stock name and ticker symbol free of charge today
BARC Barclays	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 462.12 -0.7%	GBX 510 ➝ GBX 500	Neutral
BBNX Beta Bionics	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.19 -2.7%	$28.00	Overweight
BDC Belden	Initiated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Fraser Jamieson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$114.31 +1.1%	$140.00	Buy
BFAM Bright Horizons Family Solutions	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Toni Kaplan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$66.63 +2.6%	$68.00 ➝ $66.00	Underweight
BLSH Bullish	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Vafi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$40.10 -1.5%	$45.00	Buy
BMY Bristol Myers Squibb	Reiterated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$61.14 -1.8%	$63.00	Neutral
BOKU Boku	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 132 +7.3%	GBX 200 ➝ GBX 210	Buy
BOKU Boku	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 132 +7.3%	GBX 263	Buy
BP BP	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 542.30 -0.1%	GBX 550 ➝ GBX 675	Neutral ➝ Overweight
BP BP	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Lofting Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$44.48 +3.2%		Neutral ➝ Overweight
BSVN Bank7	Target Set by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$55.10 +1.0%	$62.00
BSVN Bank7	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Woody Lay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$55.10 +1.0%	$56.00 ➝ $62.00	Outperform
BSX Boston Scientific	Target Set by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$44.58 -0.8%	$48.00
BX Blackstone	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Brown Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$119.19 -3.9%	$122.00	Neutral
CAIXY CaixaBank	Upgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$4.92 -0.8%		Buy
CBZ CBIZ	Downgraded by	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Timothy Mchugh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$54.64 -0.1%		Outperform ➝ Market Perform
CCP Celtic	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 180 +2.9%	GBX 215	Buy
CFG Citizens Financial Group	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$64.61 -1.3%	$80.00 ➝ $77.00	Hold
CGNX Cognex	Reiterated by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Summerville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$58.19 -1.3%	$65.00	Neutral
CGNX Cognex	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Eastman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$58.19 -1.3%	$78.00 ➝ $70.00	Neutral
CIFR Cipher Mining	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.35 -3.9%	$23.00	Neutral ➝ Buy
CLDX Celldex Therapeutics	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Judah Frommer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$31.12 -7.1%	$50.00 ➝ $57.00	Overweight
CLDX Celldex Therapeutics	Target Raised by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$31.12 -7.1%	$70.00 ➝ $88.00	Outperform
CMI Cummins	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tami Zakaria Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$524.51 -0.3%	$690.00 ➝ $600.00	Neutral
CMPX Compass Therapeutics	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1.17 -5.6%		Market Outperform
CMPX Compass Therapeutics	Target Set by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Driscoll Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.17 -5.6%	$4.00
CMPX Compass Therapeutics	Target Lowered by	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reni J. Benjamin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.17 -5.6%	$4.00	Market Outperform
CMPX Compass Therapeutics	Target Lowered by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.17 -5.6%	$4.00	Buy
CMPX Compass Therapeutics	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1.17 -5.6%		Overweight
CNI Canadian National Railway	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Hoexter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$119.61 +0.1%	$146.00 ➝ $143.00	Buy
CNR Canadian National Railway	Target Lowered by	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$168.62 +0.2%	C$192.00 ➝ C$190.00	Sector Perform
COLL Collegium Pharmaceutical	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.45 -1.4%	$50.00	Outperform
CORZ Core Scientific	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.10 -3.7%	$24.00	Buy
COST Costco Wholesale	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Drbul Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$904.70 +0.6%	$1,125.00	Buy
CP Canadian Pacific Kansas City	Target Set by	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$124.50 +0.6%	C$140.00	Outperform
CRDL Cardiol Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.77 -6.3%	$9.00	Buy
CRMD CorMedix	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.69 -1.2%	$15.00	Outperform
CWR Ceres Power	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 434.20 +0.5%	GBX 950	Buy
DCH American Axle & Manufacturing	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vanessa Jeffriess Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.68 -4.0%	$8.25 ➝ $7.10	Buy ➝ Hold
DPZ Domino's Pizza	Target Lowered by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Francfort Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$296.43 -0.2%	$440.00 ➝ $325.00	Neutral
DRI Darden Restaurants	Reiterated by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Carril Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$213.46 0.0%		Overweight
EDIT Editas Medicine	Upgraded by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2.69 -7.9%	$5.00	Neutral ➝ Buy
EDR Endeavour Silver	Downgraded by	Canadian Imperial Bank of Commerce Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$13.05 -11.8%	C$25.00 ➝ C$20.00	Outperformer ➝ Neutral
ELE Elemental Altus Royalties	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$26.01	C$30.00 ➝ C$36.00
ELE Elemental Altus Royalties	Target Raised by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$26.01	C$33.00 ➝ C$36.00	Outperform
ENHA Enhanced Group	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gabie Ingoglia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.41 -5.6%	$4.00	Overweight
ENTA Enanta Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$11.95 -3.8%	$20.00	Buy
EQT EQT	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Gruber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$51.04 +0.5%	$67.00 ➝ $68.00	Buy
ERO Ero Copper	Reiterated by	Canadian Imperial Bank of Commerce Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$36.53 -2.0%		Neutral
ERO Ero Copper	Target Raised by	Canadian Imperial Bank of Commerce Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$51.46 -1.9%	C$52.00 ➝ C$56.00
Ready to give options a try? Your first trade (Ticker included) -INSIDE (Ad) Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. Send me my free guide
ESTC Elastic	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Blakey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$91.01 +2.0%	$100.00	Neutral
FBRT Franklin BSP Realty Trust	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$7.47 -3.7%		Market Outperform
FBRT Franklin BSP Realty Trust	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$7.47 -3.7%	$10.00
FDR Founders Metals	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$6.95 +2.2%	C$8.00 ➝ C$9.00
FITB Fifth Third Bancorp	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$51.72 -2.0%	$64.00 ➝ $63.00	Buy
FLT Volatus Aerospace	Target Set by	Desjardins Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$0.64 +3.2%	C$0.90	Buy
FOXA FOX	Reiterated by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Morris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$63.96 -0.5%	$85.00	Buy
FRVO Fervo Energy	Initiated by	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Malloy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.35 -0.5%	$35.00	Buy
FSLY Fastly	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rishi Jaluria Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.65 +13.7%	$25.00	Sector Perform
FSLY Fastly	Reiterated by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$29.65 +13.7%		Outperform
FSLY Fastly	Reiterated by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Frank Louthan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.65 +13.7%		Outperform
FSLY Fastly	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tal Liani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.65 +13.7%	$20.00 ➝ $22.00	Underperform
FSLY Fastly	Target Raised by	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rudy Kessinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.65 +13.7%	$21.00 ➝ $23.00	Neutral
FSLY Fastly	Target Raised by	Freedom Broker Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Almas Almaganbetov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.65 +13.7%	$32.00 ➝ $37.00	Buy
GD General Dynamics	Target Lowered by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$343.20 -0.1%	$421.00 ➝ $407.00	Market Perform
GE GE Aerospace	Target Set by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sheila Kahyaoglu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$319.69 +0.1%	$455.00 ➝ $435.00	Buy
GPK Graphic Packaging	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Detlef Winckelmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.66 +0.9%	$12.50 ➝ $11.50	Neutral ➝ Overweight
GPK Graphic Packaging	Target Set by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Arun Viswanathan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.66 +0.9%	$11.50
GS The Goldman Sachs Group	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Benjamin Gerlinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$936.96 -1.3%	$1,200.00 ➝ $1,050.00	Neutral
GTE Gran Tierra Energy	Target Raised by	Roth MKM Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$14.12 +2.5%	C$17.50 ➝ C$18.50
GTY Getty Realty	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$28.95 -1.7%		Market Outperform
GTY Getty Realty	Target Set by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$28.95 -1.7%	$39.00
HAS Hays	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 64.40 +2.2%	GBX 33 ➝ GBX 65	Neutral
HBAN Huntington Bancshares	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$15.38 -2.0%	$20.00 ➝ $19.00	Buy
HII Huntington Ingalls Industries	Target Lowered by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$269.67 -0.5%	$341.00 ➝ $327.00	Market Perform
HLN Haleon	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$9.12 -1.4%		Buy
HSBA HSBC	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 1,518.44 +0.6%	GBX 1,570 ➝ GBX 1,640	Neutral
HSBC HSBC	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$100.24 -1.3%		Neutral
HUBS HubSpot	Initiated by	FBN Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$226.60 +4.0%	$230.00	Sector Perform
HUBS HubSpot	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Taylor McGinnis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$226.60 +4.0%	$230.00	Neutral ➝ Sector Perform
HUT Hut 8	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$102.46 -3.9%	$143.00	Buy
HXL Hexcel	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Herbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$86.19 +0.2%	$115.00	Outperform
IMVT Immunovant	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$34.54 -7.4%		Buy
INVA Innoviva	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$20.24 -3.5%	$35.00	Outperform
IP International Paper	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Detlef Winckelmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.71 0.0%	$61.00 ➝ $62.00	Overweight
JDG Judges Scientific	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 3,720 -1.8%	GBX 5,600	Buy
KBH KB Home	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Bettenhausen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%	$55.00 ➝ $50.00	Hold
KBH KB Home	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rafe Jadrosich Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%	$56.00 ➝ $54.00	Neutral
KBH KB Home	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Bouley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%	$57.00 ➝ $49.00	Overweight
KBH KB Home	Target Lowered by	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James McCanless Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%	$77.00 ➝ $70.00	Market Outperform
KBH KB Home	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Dahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%		Market Perform
KBH KB Home	Target Set by	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$47.32 -2.6%	$59.00
KBH KB Home	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Lovallo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%		Buy
KBH KB Home	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$47.32 -2.6%		Outperform
KBH KB Home	Target Lowered by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Dahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$47.32 -2.6%	$53.00 ➝ $50.00	Sector Perform
KEY KeyCorp	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$20.23 -1.2%	$24.00 ➝ $23.00	Hold
KGF Kingfisher	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 344.77 +0.3%	GBX 295 ➝ GBX 320	Hold
KLC KinderCare Learning Companies	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Toni Kaplan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2.21 -5.0%	$2.50 ➝ $2.00	Underweight
KMX CarMax	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniela Haigian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$57.53 +1.2%	$44.00 ➝ $47.00	Equal Weight
KMX CarMax	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniela Haigian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$57.53 +1.2%	$44.00 ➝ $47.00	Cautious
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad) A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. Click here to learn this company's name for free today
KNX Knight-Swift Transportation	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Hoexter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$67.18 +0.1%	$98.00 ➝ $92.00	Buy
KOO Kooth	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 170 -3.4%	GBX 330	Buy
KYMR Kymera Therapeutics	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Biren Amin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$115.47 -5.4%	$140.00	Overweight
LEVI Levi Strauss & Co.	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Sole Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.63 -2.1%		Buy
LGND Ligand Pharmaceuticals	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$298.41 0.0%	$390.00 ➝ $397.00	Buy
LHX L3Harris Technologies	Target Lowered by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$239.20 -0.3%	$365.00 ➝ $346.00	Outperform
LITE Lumentum	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Genovese Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$937.00 -0.9%	$1,300.00	Buy
LKFT Lakefront Biotherapeutics American Depositary Shares	Upgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$30.72 +1.8%		Buy
LKFT Lakefront Biotherapeutics American Depositary Shares	Upgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.72 +1.8%	$26.00 ➝ $45.00	Sector Perform ➝ Outperform
LTH Life Time Group	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Randal Konik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$39.64 +3.8%		Buy
LTH Life Time Group	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Arpine Kocharyan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$39.64 +3.8%	$63.00
LXEO Lexeo Therapeutics	Reiterated by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Roanna Ruiz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.52 -13.5%	$15.00	Outperform
MAZE Maze Therapeutics	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.09 -1.0%	$48.00	Outperform
MAZE Maze Therapeutics	Initiated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Joseph Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.09 -1.0%	$50.00	Buy
MDGL Madrigal Pharmaceuticals	Initiated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Joseph Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$513.02 -1.1%	$725.00	Outperform ➝ Buy
MDLN Medline	Reiterated by	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$34.30 -0.4%		Outperform
MELI MercadoLibre	Initiated by	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$1,799.24 -1.5%	$2,450.00	Buy
META Meta Platforms	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Patterson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$744.10 +1.0%	$780.00 ➝ $900.00	Overweight
META Meta Platforms	Target Raised by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Deepak Mathivanan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$744.10 +1.0%	$680.00 ➝ $860.00	Overweight
META Meta Platforms	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Ju Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$744.10 +1.0%		Overweight
MGY Magnolia Oil & Gas	Target Set by	Williams Trading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$24.41 +1.6%	$32.00
MGY Magnolia Oil & Gas	Upgraded by	Siebert Williams Shank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$24.41 +1.6%	$30.00 ➝ $32.00	Hold ➝ Buy
MNG M&G	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 329 -0.5%	GBX 335	Sector perform
MNO Meridian Mining UK Societas	Target Raised by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$1.03 +9.6%	C$2.75 ➝ C$3.00	Outperform
MNO Meridian Mining UK Societas	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$1.03 +9.6%	C$3.25 ➝ C$4.00	Buy
MSFT Microsoft	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Karl Kierstead Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$500.59 +0.5%		Buy
MSFT Microsoft	Downgraded by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$500.59 +0.5%		Outperform ➝ Underperform
MSFT Microsoft	Initiated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$500.59 +0.5%		Buy
MSFT Microsoft	Downgraded by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Zukin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$500.59 +0.5%		Outperform ➝ Peer Perform
MTB M&T Bank	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$219.55 -1.7%	$268.00 ➝ $250.00	Hold
MU Micron Technology	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Timothy Arcuri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,071.88 -2.2%		Buy
MU Micron Technology	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Aaron Rakers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,071.88 -2.2%	$1,525.00 ➝ $1,400.00	Overweight
MU Micron Technology	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Atif Malik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,071.88 -2.2%	$1,150.00 ➝ $1,300.00	Buy
NHI National Health Investors	Reiterated by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Juan Sanabria Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$67.25 -0.2%		Outperform
NKE NIKE	Target Set by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Nagel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.95 -0.4%	$60.00 ➝ $52.00	Outperform
NKE NIKE	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adrienne Yih Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.95 -0.4%	$52.00 ➝ $48.00	Overweight
NKE NIKE	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Drbul Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.95 -0.4%	$55.00	Buy
NKTR Nektar Therapeutics	Target Lowered by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Fan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$57.66 -5.4%	$80.00 ➝ $50.00	Neutral
NOC Northrop Grumman	Target Lowered by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$514.47 +0.9%	$653.00 ➝ $620.00	Market Perform
NP Neptune Insurance	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$27.61 +0.2%		Buy
NWG NatWest Group	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 684 -1.6%	GBX 840 ➝ GBX 860	Buy
O Realty Income	Downgraded by	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nicholas Yulico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$55.55 -1.7%	$59.00	Sector Outperform ➝ Sector Perform
ONON ON	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Sole Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.13 +2.5%		Buy
ONON ON	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$30.13 +2.5%		Buy
ONON ON	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Janine Stichter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.13 +2.5%	$60.00	Buy
ONON ON	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tom Nikic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.13 +2.5%	$37.00 ➝ $40.00	Buy
ORIC Oric Pharmaceuticals	Initiated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeet Mukherjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.33 -1.3%	$26.00	Buy
PALI Palisade Bio	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mitchell S. Kapoor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.60 -5.3%	$7.00	Buy
PATH UiPath	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bryan C. Bergin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%	$16.00	Hold
PATH UiPath	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Berg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%	$22.00	Buy
Your $29.97 book is free today (Ad) Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. Normally $29.97. Today it's free. Grab your copy now.
PATH UiPath	Target Lowered by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Hedberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%	$17.00 ➝ $15.00	Sector Perform
PATH UiPath	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Radi Sultan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%	$19.00 ➝ $15.00	Neutral
PATH UiPath	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Tillman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%	$17.00 ➝ $14.00	Hold
PATH UiPath	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Hedberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%		Outperform
PATH UiPath	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Radi Sultan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$13.05 -1.5%		Buy
PBR Petroleo Brasileiro S.A.- Petrobras	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matheus Enfeldt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$21.15 +1.9%	$22.00 ➝ $23.00	Buy
PCRX Pacira BioSciences	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$24.63 -0.3%	$32.00	Outperform
PEP PepsiCo	Target Lowered by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Grundy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$130.18 -0.8%	$183.00 ➝ $161.00	Outperform
PHAR Pharming Group	Target Set by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$10.77 -4.4%	$38.00
PKG Packaging Corporation of America	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Detlef Winckelmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$241.15 +1.2%	$312.00 ➝ $320.00	Overweight
PLSE Pulse Biosciences	Initiated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$51.98 -1.3%	$70.00	Buy
PLTR Palantir Technologies	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John McPeake Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$191.79 +3.7%	$225.00	Buy
PM Philip Morris International	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faham Baig Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$190.61 +0.2%	$182.00 ➝ $193.00	Neutral
PM Philip Morris International	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faham Baig Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$190.61 +0.2%	$182.00 ➝ $192.00	Neutral
PMP Portmeirion Group	Reiterated by	Shore Capital Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 50 -2.0%		House Stock
QNRX Quoin Pharmaceuticals	Initiated by	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Flaten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$6.75 -3.7%	$20.00	Buy
RAPP Rapport Therapeutics	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$34.13 -17.7%		Market Outperform
RAPP Rapport Therapeutics	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$34.13 -17.7%	$80.00
RBA RB Global	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sabahat Khan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$82.86 -0.6%	$152.00	Outperform
RBLX Roblox	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bernie McTernan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$48.99 -1.8%	$50.00 ➝ $55.00	Buy
RBRK Rubrik	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shrenik Kothari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$116.04 +3.7%	$130.00 ➝ $139.00	Outperform
RCL Royal Caribbean Cruises	Reiterated by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tristan Thomas-Martin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$230.09 -2.0%	$370.00	Outperform
RCL Royal Caribbean Cruises	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robin Farley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$230.09 -2.0%		Buy
RCL Royal Caribbean Cruises	Reiterated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$230.09 -2.0%		Outperform
RF Regions Financial	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Foran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$27.38 -1.9%	$34.00 ➝ $31.00	Hold
RKH Rockhopper Exploration	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 66.90 +0.5%	GBX 130 ➝ GBX 135	Buy
ROL Rollins	Downgraded by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Keith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$32.45 -1.3%	$33.00	Neutral
RTO Rentokil Initial	Upgraded by	Investec Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$21.45 +0.4%		Buy
RTX RTX	Target Lowered by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$192.24 +0.7%	$232.00 ➝ $223.00	Market Perform
RXO RXO	Upgraded by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bascome Majors Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.88 +0.4%	$20.00 ➝ $19.00	Negative ➝ Neutral
RXO RXO	Target Set by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Wadewitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.88 +0.4%	$19.00
SCBFF Standard Chartered	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$29.47 -4.1%		Neutral
SDE Spartan Delta	Target Set by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		C$12.94 +2.8%	C$17.00	Outperform
SDI SDI Group	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 91.20 -3.0%	GBX 145	Buy
SDLF Standard Life	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 938 +0.4%	GBX 885 ➝ GBX 970	Sector perform
SFM Sprouts Farmers Market	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Carden Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$66.07 -3.8%		Neutral
SHOP Shopify	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ygal Arounian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$142.34 -3.7%	$176.00	Outperform
SKHY SK hynix	Reiterated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Caso Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$189.28 -3.1%	$250.00	Outperform
SMGZY Smiths Group	Downgraded by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$36.98 -1.1%		Buy ➝ Neutral
SMIN Smiths Group	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 2,785 +0.1%	GBX 3,000 ➝ GBX 3,200	Buy
SMMT Summit Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mitchell S. Kapoor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.45 -3.9%		Neutral
SMMT Summit Therapeutics	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Dai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.45 -3.9%		Neutral
STAN Standard Chartered	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 2,279 +0.6%	GBX 2,230 ➝ GBX 2,370	Neutral
STZ Constellation Brands	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Grom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$116.36 -1.0%	$168.00 ➝ $145.00	Buy
SUNS Sunrise Realty Trust	Upgraded by	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$7.35 -3.4%		Sell ➝ Neutral
SVCO Silvaco Group	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Blair Abernethy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.26 +2.7%	$14.00	Buy
SW Smurfit Westrock	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Detlef Winckelmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$46.59 +0.3%	$68.00 ➝ $69.00	Overweight
TEL TE Connectivity	Initiated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Varun Govindaraj Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$214.60 +0.5%	$243.00	Outperform
TEVA Teva Pharmaceutical Industries	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$39.10 -1.1%	$50.00	Outperform
THO Thor Industries	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Kennison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.01 -2.4%	$90.00 ➝ $80.00	Neutral
THO Thor Industries	Reiterated by	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Stember Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.01 -2.4%	$74.00	Neutral
TLSI TriSalus Life Sciences	Target Set by	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$5.00 +1.4%	$12.00
TLSI TriSalus Life Sciences	Target Set by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$5.00 +1.4%	$12.00
TLSI TriSalus Life Sciences	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.00 +1.4%	$11.00 ➝ $12.00	Buy
TLX Telix Pharmaceuticals	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$11.27 -5.7%	$22.00	Outperform
TTC Toro	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kristen Owen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$96.65 +2.3%	$120.00	Outperform
TTE TotalEnergies	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Lofting Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$91.69 +2.1%		Overweight ➝ Neutral
TTI Tetra Technologies	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Gengaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.98 -0.7%	$13.00 ➝ $12.00	Buy
VIAV Viavi Solutions	Target Set by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ruben Roy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$36.43 +0.1%	$65.00
VIAV Viavi Solutions	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Genovese Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$36.43 +0.1%	$70.00	Buy
VKTX Viking Therapeutics	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$41.65 +2.0%	$83.00 ➝ $87.00	Buy
VLO Valero Energy	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Neil Mehta Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$376.39 -0.2%	$365.00 ➝ $457.00	Buy
VNDA Vanda Pharmaceuticals	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Les Sulewski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.04 -3.3%	$10.00	Outperform
W7L Warpaint London	Reiterated by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 196.40 -12.3%	GBX 425	Buy
WFRD Weatherford International	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Josh Silverstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$84.66 +0.8%	$120.00 ➝ $116.00	Buy
WIX Wix.com	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bernie McTernan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$76.80 -4.1%	$80.00 ➝ $95.00	Buy
WLDN Willdan Group	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Wahrhaftig Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$81.36 +1.8%	$130.00	Outperform
WULF TeraWulf	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$16.35 -5.7%	$24.00	Buy
WVE WAVE Life Sciences	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tessa Romero Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.95 -9.2%		Overweight ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:51 PM ET.

Stock Ratings and Recommendations: Understanding Analyst Ratings

Written by MarketBeat Staff

Key Points

Stock analysts give ratings to companies based on their research and insights.
Analysis comes from the buy side (fund companies, investment managers) or sell side (brokers, banks).
Analysts use different methodologies, so investors should always look into why a particular rating was given.
5 stocks we like better than EXA)

You'll often hear a particular stock called a "buy" or "sell," but who exactly makes these calls? Ratings and recommendations come from stock analysts, who research different securities and work for various institutions, brokerage firms and other financial companies.

Analyst ratings are designed to give additional information to investors beyond just what the company is saying, but are analyst ratings reliable? In this article, we'll discuss how to read analyst ratings, what goes into their decision-making process and how potential conflicts of interest influence analyst stock ratings.

What Are Analyst Ratings?

A stock rating is a simple heuristic given by analysts who review the firm's financial statements, listen to conference calls, chat with company executives and compare the stock to others in the industry or sector. Finally, an analyst uses all this information to produce a simple recommendation and price target.

When a public analyst goes on CNBC or the "Wall Street Journal" to give a "buy" or "sell" rating on a particular stock, they take all their research and pare it down into a simple designation. While there's no true consensus on what constitutes a buy or sell rating, an analyst usually does have "skin in the game" when devising ratings.

Ratings often pair with price targets, which put a hard number on what the analysts believe the company stock should be worth. So, for example, you might see an analyst report something like, "Buy NVIDIA Inc. (NASDAQ: NVDA), price target $350," which means that particular analyst believes investors should buy NVDA shares up to a price of $350 per share.

Analyst ratings infographic: What you need to know

What Does a Stock Analyst Do?

A stock analyst is a market professional with the skills to interpret financial data and the connections within companies to speak on the record with higher-ups. Analysts generally fall into one of two different camps: buy-side or sell-side. These positions will seem similar, but they tend to be employed by various institutions and have different responsibilities in their particular market "territories."

Buy-side analysts: Analysts on the buy side tend to work for funds, such as ETF providers or hedge funds. They don't dig as deeply into company financial data or conference calls as sell-siders. Instead, they focus on general areas or industries where their funds have vested interests. In addition, buy-side analysts often forge relationships with sell-side analysts for individual stock research. A buy-side analyst's primary goal is to find and utilize the most accurate and dependable sell-side analysts.
Sell-side analysts: If buy-side analysts work for funds (i.e., institutions that buy securities), you can probably guess which type of institution employs sell-side analysts. Brokers, banks and other firms that sell securities to investors use sell-side analysts to give reports to the public. While buy-side analysts also give ratings and price targets, the reported "buy" and "sell" ratings in financial media typically come from folks on the sell side.

Buy and sell-side analysts often use different rating systems when making their recommendations. You might even find two sell-side analysts with similar "buy" recommendations with vastly different price targets in the same stock. As a result, you'll need to familiarize yourself with the various methodologies analysts use to utilize their research correctly.

What Ratings Do Analysts Give?

Stock analyst ratings don't follow a strict structure, although most have roughly the same grading system for the securities they review. The labels may differ slightly (i.e., overweight vs. outperform), but the five most common analyst ratings go like this.

Buy

Analysts bullish on a particular security will give it a "buy" rating and set a price target above the current market price. In addition, if the analyst considers the stock one of the best in the industry or sector, you'll sometimes see a "strong buy" rating attached.

Hold

A "hold" rating is typically the lowest rating a sell-side analyst gives a stock. "Hold" means the analyst projects the stock to meet the return of the market averages, making it an unspectacular investment. Stocks rated "hold" may still have a price target above the current price, but it's not likely to surpass the return of a major index like the S&P 500.

Sell

Analysts are usually apprehensive about giving a stock a "sell" rating. For example, suppose a "hold" rating indicates indecision over the stock's future. In this scenario, a "sell" rating is issued when an analyst finds something unappealing, such as questionable accounting tactics or cratering sales growth.

Underperform

Analysts won't always give a firm "buy" or "sell" rating on stock but will instead label it "underperform" or "outperform." "Underperform" means the analyst expects the stock not to keep up with the market. It doesn't necessarily mean the analyst predicts a crash but indicates a lack of confidence in the shares.

Outperform

"Outperform" is the opposite of "underperform," meaning the analyst expects the stock to do better than the market average. It's usually considered a less confident rating than "buy."

Example of an Analyst Rating

You can use MarketBeat Analyst Ratings to find ranges and aggregates from buy- and sell-side analysts across the financial media. For example, here's a stock that analysts usually love: Alphabet Inc. (NASDAQ: GOOG).

Overview of stock analysis on GOOG Using MarketBeat's tools, you can find ratings from prominent analysts from multiple periods. Alphabet is currently labeled a "moderate buy" based on MarketBeat's consensus from 17 analysts. You'll get the consensus price target and the highest and lowest from the analysts surveyed.

Marketbeat's tools detailing analyst ratings

Looking at analyst recommendations over time is another helpful tool. For example, you can view the different levels of coverage over the last few years, which analysts changed their ratings and how the price targets vary from month to month. If an analyst can't get a good read on a particular stock they've been covering, they might choose to withhold their grade, which is one reason why the number of available ratings can change over time.

Overview of analyst ratings on MarketBeat Analysts from both sides of the aisle can be found on MarketBeat, ranging from large firms like JPMorgan Chase and Co. (NYSE: JPM) to smaller investment banks like Roth Capital. Some institutions like UBS Group offer both buy-side and sell-side ratings and analysis. These graphs show that even analysts with similar ratings can have vastly different price targets, so always understand the reasoning behind an analyst's view.

How to Use Analyst Ratings

Here are a few pointers on incorporating analyst ratings into your investment research.

Step 1: Don't rely on a single analyst.

Using an array of analysts (buy- and sell-side) gives inventors the most possible information. Don't just look for analysts with similar opinions as yourself — ensure you understand the pros and cons of each investment you make by incorporating positive and negative views, if possible.

Step 2: Compare analyst ratings across the industry or sector.

It's easy to slap a "buy" rating on a stock and predict a winner, but comparing stocks against others in the sector can offer insight into the rating. For example, if a stock is rated "buy" in the information technology sector, but a dozen others are rated "strong buy" by the same analyst, where is your capital best served?

Step 3: Consider your own goals and risk tolerance.

You might find stocks rated "strong buy" in your research in sectors you wish to avoid. That's fine! There are thousands of securities across dozens of industries in the public markets, and you don't need to purchase every share that comes with a "buy" rating. Instead, stick to your investment plan.

Step 4: Don't stubbornly stick to your original assessments.

Following your investment plan and using analyst ratings as guidelines are practical steps, but things can change over time. Today's "strong buy" stocks could be "strong sell" stocks down the road. Using an aggregate of analysts' ratings can help investors view stocks from a higher level. For example, if the number of "buy" ratings on a stock drops 40% over a few years, you might want to take a closer look at that particular company.

Why Are Analyst Ratings Important?

Checking out analyst ratings isn't a necessary step for investing, but it can be helpful for those looking to dig deep into an asset's prospects. Analyst research often has quotes from company executives, questions from conference calls and in-depth reporting on the company's balance sheet, income statement and other essential documents. Analysis like this is complex for individual investors to do on their own, especially considering how frequently analysts interact with the executives they cover. But access often comes with a downside, which we discuss more below.

How Accurate Are Analyst Ratings?

Both buy and sell-side analysts strive for accuracy because giving consistently wrong commendations can be hazardous for job security. However, investors should be aware that analysts might not always have the best interest of the retail investor at heart when making their recommendations.

For starters, being an analyst requires access to company employees and management. Analysts typically ask questions during conference calls and speak with C-suite executives on the record about their firms' prospects. Executives usually don't want to hear adverse reports about their companies, so analysts are incentivized to paint a rosy picture to retain access. The SEC has been questioning the authenticity of analyst ratings (especially on the sell-side) since 2002 when it asked bluntly, "Why are there so few sell ratings?"

Of course, there are other areas of the securities analysis market to face scrutiny. If you recall, during the 2008 financial crisis, the biggest credit rating agencies were all held to the fire due to claims that conflicts of interest influenced their ratings. The biggest rating agencies in the world were accused of "misrepresenting the risks associated with mortgage-backed securities." Remember, analyst ratings aren't spat out by computer algorithms but by living, breathing people who may have agendas other than providing the most precise and accurate reports on a company's future prospects.

Analyst Ratings Can Guide Investors, but Don't Treat Them as Gospel

Consider each type of investment research or advice in collaboration. Even the most accurate and thoughtful analysts get things wrong, plus ratings are frequently besieged with conflicts of interest. But analyst coverage does offer research that's difficult to get elsewhere, and using an array of analyst reports can give investors a deeper understanding of the securities they buy.

FAQs

Still have questions about analyst ratings? Here are a few answers to some common points of discussion:

What are analyst ratings?

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Should you trust analyst ratings?

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

What does an analyst rating tell you about a stock?

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stock Price Targets and Analyst Ratings